JAB-8263

Small molecule

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Non-Small Cell Lung Cancer · Phase 1/2Myelofibrosis

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Rheumatoid Arthritis
NCT07684157 · Jacobio Pharmaceuticals Co., Ltd.
2026-07-23 – 2027-12-31 · Rheumatoid Arthritis (RA)
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
Phase 1 (1)
Other / comorbidity
NCT04587479 · Jacobio Pharmaceuticals Co., Ltd.
2020-11-23 – 2024-10-31 · Solid Tumors, Adult
What this study did

Competitive landscape

This drug's own stage for Myelofibrosis: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
JAB-8263: this drugStage not on recordSmall moleculeBET bromodomain proteins (e.g. BRD4)not yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Jakafi)ApprovedSmall moleculeJAK1/2Partial signal
NCT00934544: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 (Baseline, Week 48): Ruxolitinib 28.5 Percentage of Participants | Best Available Therapy (BAT) 0 Percentage of Participants
NCT00952289: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 (Baseline and Week 24): Ruxolitinib 65 participants | Placebo 1 participants
Jaktinib (Zepuping)Phase 3Small moleculeJAK1/2/3not yet gradedNo reviewed efficacy summary in this indication
Ropeginterferon Alfa-2b (Besremi)Phase 3Protein / enzyme therapeuticType I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
SelinexorPhase 3Small moleculeXPO1 (exportin-1)Partial signal
NCT04562389: Co-primary endpoints at week 24: SVR35 50% with selinexor plus ruxolitinib vs 28% with ruxolitinib alone (significant); Abs-TSS not met (2026-03-24).

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow JAB-8263 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 2Rheumatoid ArthritisRecruiting
Est. primary completion 2027-06-30 · NCT07684157 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01 · NCT04686682 · CT.gov ↗
What to watch

See the full readout calendar ↗